Nefopam

This classification denotes a benzodiazepine with the molecular formula C17H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4UP8060B7J, chemically known as 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1h-2,5-benzoxazocin but generally known as nefopam, which bears US NIH Compound Identifier 4450. European Medicines Agency schedules Nefopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09183MIG. The term NEFOPAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). World Health Organization schedules nefopam in its Anatomical Therapeutic Chemical (ATC) Classification. NEFOPAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nefopam under HS 29349990 and SITC 51579. As of Q4 2014, NEFOPAM remains the US FDA Preferred Term for this commodity. Nefopam bears US NLM identifiers UMLS ID C0027556 and NCI Concept Code C83994. SMILES: O1C(C2C(CN(CC1)C)CCCC2)C1CCCCC1.